{
  "report_rows": [
    {
      "kpi": "Fiscal Q4 2026 revenue",
      "prediction": "BEAT",
      "answer": "pred ~$1.480B vs. cons $1.465B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Fiscal Q4 2026 non-GAAP diluted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$2.95 vs. cons $2.90",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Fiscal Q4 2026 non-GAAP gross margin",
      "prediction": "IN-LINE",
      "answer": "pred ~62.9% vs. cons 62.8%",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "Fiscal 2027 reported revenue",
      "prediction": "LOWER",
      "answer": "guide ~$5.90B vs. cons $5.93B (FY2027)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Fiscal 2027 non-GAAP diluted EPS",
      "prediction": "LOWER",
      "answer": "guide implied ~$11.85 vs. cons $11.95 (FY2027)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Fiscal 2027 non-GAAP gross margin",
      "prediction": "BETTER",
      "answer": "guide midpoint ~63.3% vs. cons 63.2% (FY2027)",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": -2.2,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": -3.8,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "A modest Q4 beat is outweighed by FY2027 non-GAAP EPS implied at ~$11.85 versus consensus of $11.95; MatrixCare profit removal, Noctrix dilution and elevated investment spending drive estimate reductions despite buyback support and slight gross-margin upside.",
  "day5_confidence": "MEDIUM"
}